Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.
|Articles|April 15, 2016
- Gastrointestinal Special Issue
- Volume 1
- Issue 1
Medical Illustration: Targeting HER2 in Gastric Cancer
Author(s)Erin Moore
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Advertisement
ILLUSTRATION BY ERIN MOORE
ORIGINALLY PUBLISHED IN “GUT REACTION,” CURE WINTER 2009
*HER2 is also associated with breast cancer.
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Articles in this issue
over 10 years ago
In Gastroesophageal Cancers, Better Prevention and Treatments Neededover 10 years ago
An Insight Into Gastric Cancers and Life Without a Stomachover 10 years ago
Changing Lives With ImmunotherapyAdvertisement
Related to this article
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Jemperli for dMMR Locally Advanced Rectal Cancer
2
Gemcitabine Plus BCG Clears Bladder Cancer in 96% of Patients After BCG Failure
3
Diagnosed With Sarcoma at 21, She Found Her People at Mary's Place
4
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
5